Arylacetamide Deacetylase Is Involved in Vicagrel Bioactivation in Humans
Vicagrel, a structural analog of clopidogrel, is now being developed as a thienopyridine antiplatelet agent in a phase II clinical trial in China. Some studies have shown that vicagrel undergoes complete first-pass metabolism in human intestine, generating the hydrolytic metabolite 2-oxo-clopidogrel...
Uloženo v:
| Hlavní autoři: | , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Frontiers Media S.A.
2017-11-01
|
| Edice: | Frontiers in Pharmacology |
| Témata: | |
| On-line přístup: | http://journal.frontiersin.org/article/10.3389/fphar.2017.00846/full |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|